

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

LOAN FACILITY OF HK\$1.1 BILLION - ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

The Company, as borrower, has entered into the Facility Agreement for a term loan facility up to HK\$1.1 billion. The Facility Agreement imposes, among other matters, specific performance obligations on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces that the Company, as borrower, has entered into a facility agreement (the “Facility Agreement”) with China Merchants Bank Co., Ltd., Singapore Branch (as mandated lead arranger and bookrunner), Industrial Bank Co., Ltd., Hong Kong Branch, and Pingan Bank Co., Ltd. for a term loan facility up to HK\$1.1 billion. The loans under the Facility Agreement shall be repaid in installments as 10%, 10% and 80% of the loan amounts on the dates falling 12, 24 and 36 months respectively after the first utilisation of the facility.

The Facility Agreement imposes that, among other matters, Mr. Tsoi Hoi Shan, Ms. Choy Siu Chit, Ms. Ning Kwai Chun and their family trusts collectively, directly or indirectly (i) constitute the single largest shareholder of the Company; (2) own not less than 40% of the issued share capital of the Company, and (iii) do not cease management control over the Company or the Group.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

On behalf of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 8 November 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.